Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) trading at the highs of the session following FDA approval. Shares are up 90.7%
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta's (SRPT) Exondys 51 covered by Humana (HUM) with prior authorization - Bloomberg
- Stocks with Implied Volatility Movement
- BioCryst Pharma (BCRX) Shares Ramp to Session Highs Amid Upcoming Galidesivir Data Presentation
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!